Inhaled Nitric Oxide Tested in Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Tests inhaled nitric oxide for exercise capacity in adults with lung disease, COPD.
Plain-language title generated from the registry record
Registry title: A Clinical Study of Inhaled Nitric Oxide in Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Key facts
- Where
- Nanjing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT05896800, who can take part
Where in China
- The First Affiliated Hospital with Nanjing Medical UniversityNanjing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital with Nanjing Medical University
- Trial code
- NCT05896800
- Record updated
- 18 June 2025
- Original description
The purpose of this study is to evaluate the influence of exercise capacity and safety of iNO at doses of 10 ppm or 40 ppm for 2 hours per day after continuous treatment for one week, which is of great significance for finding safe and effective methods for treating COPD.Read full original descriptionShow less
Efficacy and Safety of Inhaled Nitric Oxide in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease: a Prospective, Single-center Clinical Trial
The purpose of this study is to evaluate the influence of exercise capacity and safety of iNO at doses of 10 ppm or 40 ppm for 2 hours per day after continuous treatment for one week, which is of great significance for finding safe and effective methods for treating COPD.
Inclusion: Age ≥ 40 years, ≤ 75 years; Previous smoking history ≥ 10 pack-years, and had stopped smoking for one month before study entry; Met the diagnosis criteria of moderate and severe COPD: a post-bronchodilator FEV1/FVC < 0.7, and 30%< FEV1 < 80% predicted; Signed informed consent and performed all the study mandated procedures.
Exclusion: Experienced during the last month an exacerbation requiring start of or increase in systemic oral corticosteroid therapy; Use of investigational drugs or devices within 30 days prior to enrollment into the study; A diagnosis of asthma or other non-COPD respiratory disease, in the opinion of the Investigator; Clinically significant valvular heart disease, including aortic valvular disease (moderate or severe aortic stenosis or regurgitation) and/or mitral valve disease (moderate or severe mitral stenosis or regurgitation), or status post mitral valve replacement; Use within 30 days of screening or current use of approved pulmonary hypertension medications such as sildenafil, bosentan or prostacyclines; Any underlying medical or psychiatric condition that, in the opinion of the Investigator, makes the subject an unsuitable candidate for the study; Left ventricular systolic dysfunction: left ventricular ejection fraction (LVEF) < 50%; Pregnant or lactating women; Current or recent month user of nicotine-like substances (including nicotine patches, etc.); Lack of patency of nares upon physical examination.